ShanghaiTwo genetic-treatment trials stalled after deaths and new government rules.
Rare-disease families lose the fastest route to experimental genetic treatments in China.
In China, investigator-initiated trials start without sign-off from central regulators, cutting the cost and time of testing drugs.
Juan Huang’s Hope for Rare Foundation was on track for two more trials until this summer’s deaths and new rules upended them.
How each outlet framed it
- STAT leans critical
- traces the trial pipeline through one family's case, from a 2014 diagnosis abroad to two IIT trials cut by summer deaths and new rules
Sources: STAT